Our Team

Management

Portrait of Steve Sadoff

Steve Sadoff,
Co-founder and CEO

Steve has more than fifteen years of leadership experience developing and launching products in regulated markets including nutraceuticals, alcohol, pharmaceuticals, and natural health. With a proven track record of growing sales, building brands, and leading product-development teams for Bacardi, Labatt, Novartis, and Jamieson Laboratories, Steve has led the successful introduction of nearly one hundred innovative products.

Mark Goliger,
President

Mark has over twenty years experience leading Strategy, Operations and Sales within a variety of industries including Healthcare.  An accomplished C-Suite Executive with multiple successes in high growth, small-cap environments, Mark is a transformational and results oriented leader with high EQ and a demonstrated ability to increase shareholder value in hyper-competitive industries.  Prior to joining GoodCap, Mark was the Chief Executive at Meta Growth Corp. where he led financings of over $100 million, oversaw their public listing (META TSX-V) and their subsequent acquisition by High Tide Inc.

Dr. Ralph Landau,
Chief Science Officer

Ralph is a highly skilled and experienced executive with a career spanning over thirty years leading R&D, compliance, manufacturing, and operations across a variety of pharmaceutical companies including Sandoz, Novartis, and Merck. He has led the commercialization of over 50 products covering a number of dosage forms, including Veregen, the first ever botanical drug approved by the FDA. Formally trained as a Ph.D. chemical engineer, Ralph has spent significant time in both generic and branded businesses and has a deep understanding of pharmaceutical drugs’ development & manufacturing processes.

Portrait of Dr. Daryl Hudson

Dr. Darryl Hudson,
Co-founder and Chief Innovation Officer

Darryl has deep expertise in molecular biology, neuroscience, and genetics in psychedelics. He holds a PhD in molecular biology and genetics. Prior to founding GoodCap, Darryl co-founded InPlanta Biotechnology Inc. and Pathways Rx, where he led the development and commercialization of proprietary plant genetics. He has also co-authored numerous peer-reviewed research articles on plant biology, genetics, DNA repair, epigenetics, and cancer.

Portrait of Irie Selkirk

Irie Selkirk,
Co-founder and Advisor

Irie is a trailblazer in the natural medicine and psychedelics industries who believes that the thoughtful and intentional consumption of medicines and mindful healing can infuse our lives with purpose. She founded Rise Wellness, the world’s first microdose psilocybin retreat, and co-founded Sansero Life Sciences and the Toronto support chapter of MAPS Canada. Irie’s deep knowledge of natural substances and their healing properties spans multiple industries. She has extensive experience in consumer strategy, outreach, and education and speaks at conferences and seminars around the world.

Dr. Igor Kovalchuk,
Laboratory Principal

Igor has more than twenty years of experience in plant biotechnology, genetics, and breeding with a research focus on medicinal plants. He is professor and Board of Governors Research Chair at the University of Lethbridge, has written more than 150 peer-reviewed publications, and holds numerous patents and pending patents.

Board of Directors

Rochelle Stenzler,
Chair

Rochelle served as Chair of the Board of publicly traded (TSX & NASDAQ) Cynapsus Therapeutics Inc., until it was acquired for C$841 million by Sunovion Pharmaceuticals Inc. in late 2016. She is currently the Chair of Spartan Bioscience Inc. and recently concluded a 9 year term where she served as a Board Director & Vice Chair of the Humber River Hospital in Toronto, Canada. Rochelle has extensive experience as a senior executive in retailing, consumer packaged goods, IVR technology & health care services, having held a variety of executive leadership roles including President of Revlon Canada Inc. and President & General Manager of Pharma Plus Drugmarts Ltd.

Dr. Joseph Elliot

Joseph is founder and President of Biopharm Management Inc., a consulting practice through which he has advised pharmaceutical, diagnostic, and biotech companies for twenty years. His skills and experience include raising capital, financing, licensing, drug development, manufacturing, and regulatory affairs. For the past 29 years he has been a serial entrepreneur and venture capitalist. He has broad experience in pharmaceuticals, biologicals and vaccines in oncology and infectious diseases. Prior to becoming an entrepreneur, Joseph held senior technical and international marketing positions with Pharmacia Canada Inc. (now Pfizer) and Connaught Laboratories Inc. (now Sanofi-Pasteur Vaccines). He received his PhD in Medical Sciences from McMaster University.

Carol Coughlin

Carol is an experienced board leader who specializes in auditing and risk and helps teams navigate corporate governance, IPOs, strategy, and M&A for highly regulated companies. She is an accomplished healthcare CFO and a certified public accountant with a track record of achieving profitability through growth, turnarounds, and M&A. She was highly involved in the sale of three private companies with nine-figure revenues to large, national public companies. Carol is currently managing director of a growth-advisory firm and serves on the board of the University of Maryland Medical Center and TrustyCare, an early stage Insure-Tech company.

Ted Chung

Ted Chung has more than twenty years of success in branding, corporate consulting, and communication strategy. Based in Los Angeles, he is the founder of a premiere diversity agency working with clients ranging from the largest streaming platforms & television studios to global consumer product goods brands. Ted is also a Co-Founder of venture capital firm Casa Verde Capital and has launched Emmy-nominated media platforms.

Lorne Gertner

Lorne is a co-founder of GoodCap Wellness. His prior experience in drug development includes co-founding Cannasat Therapeutics, which later became Cynapsus Therapeutics which sold to pharmaceutical giant Sunovion Pharmaceuticals Inc. in 2016 for C$841 million. As a pioneer within disruptive industries, he co-founded and is the former chairman of PharmaCan Capital Corporation, now doing business as the publicly traded (TSX) Cronos Group Inc. He is also a co-founder of the Tokyo Smoke brand which is now owned by Canopy Growth after a purchase in 2018.

Portrait of Steve Sadoff

Steve Sadoff

Steve has more than fifteen years of leadership experience developing and launching products in regulated markets including nutraceuticals, alcohol, pharmaceuticals, and natural health. With a proven track record of growing sales, building brands, and leading product-development teams for Bacardi, Labatt, Novartis, and Jamieson Laboratories, Steve has led the successful introduction of nearly one hundred innovative products.

Advisors

Steve Sadoff

Lorem ipsum dolor sit amet, consectetur adipiscing elit. Etiam et nibh nibh.